Immunovant, Inc. beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q12027 FY2027 | $-0.66 | $-0.75 | -13.6% | Miss |
| Q42026 FY2026 | $-0.60 | $-0.73 | -21.7% | Miss |
| Q32026 FY2026 | $-0.72 | $-0.61 | +15.3% | Beat |
Back to IMVT overview · IMVT holders · IMVT KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.